Liver Failure clinical trials
25 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
- Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
- A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
- Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
- Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
- A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
- The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
- A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
- A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
- Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants
- Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
- Empagliflozin in Patients With Cirrhosis and Ascites
- A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
- A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
- A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
- A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
- TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation
- MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
- VitaSmart HOPE System: Bridge to HOPE Registry
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Liver Failure” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.